W
Winfried Häuser
Researcher at Technische Universität München
Publications - 389
Citations - 19998
Winfried Häuser is an academic researcher from Technische Universität München. The author has contributed to research in topics: Fibromyalgia & Chronic pain. The author has an hindex of 61, co-authored 361 publications receiving 15838 citations. Previous affiliations of Winfried Häuser include University of Duisburg-Essen.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of meditative movement therapies in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled trials
TL;DR: Yoga had short-term beneficial effects on some key domains of FMS and MMT are safe, with a need for high-quality studies with larger sample sizes to confirm the results.
Journal ArticleDOI
Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome
TL;DR: The SNRIs duloxetine and milnacipran provided a small incremental benefit over placebo in reducing pain and sleep problems, and did not improve QOL substantially.
Journal ArticleDOI
Validation of the Fibromyalgia Survey Questionnaire within a Cross-Sectional Survey
Winfried Häuser,Eva Jung,Brigitte Erbslöh-Möller,Mechthild Gesmann,Hedi Kühn-Becker,Franz Petermann,Jost Langhorst,Thomas S. Weiss,Andreas Winkelmann,Frederick Wolfe +9 more
TL;DR: The study demonstrated the feasibility of theFSQ in a cross-sectional survey with FMS-patients and validated the reliability, convergent and discriminant validity of the FSQ were good.
Journal ArticleDOI
Predictors of reduced health-related quality of life in adults with coeliac disease
TL;DR: This study highlights the need to understand more fully the determinants of quality of life in coeliac disease that are not consistent and how these can be influenced by diet, exercise and other factors.
Journal ArticleDOI
Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis.
TL;DR: AMT cannot be regarded as the gold standard of FMS therapy with antidepressants because of the methodological limitations of its trials and there were no significant differences in acceptability of the three drugs.